Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D185 in Advanced Solid Tumors
NCT04221204Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of segigratinib in solid tumor, sponsored by 3D Medicines Inc. Primary endpoint: Adverse Events at 24 months. Started Sep 2019; status: completed.
02
Drugs
segigratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04221204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221204.